MOSCOW (MRC) -- Evonik Industries, the German specialty chemicals company, has announced a significant expansion of its Jurong Island, Singapore oil additives plant, to be completed in early 2015, according to the company's press release.
With ongoing improvement and debottlenecking projects scheduled to be finalized during the first half of 2014, these optimizations and the planned expansion will nearly double the capacity of the oil additives plant in Singapore.
Evonik’s initiative is a response to the above-average growth in the oil additives market due to expanding mobility and increasing demand for high-performance lubricants with higher additive content in Asia.
"As a market and technology leader in high-performance additives, we’re strengthening our position in Asia. Our expansion strategy supports the growth of our customers directly from a modern, efficient local production center, with logistics that make a contribution to resource efficiency at the same time," says Dr. Thomas Haeberle, Executive Board member of Evonik with responsibility for the company’s Resource Efficiency segment.
From 2015, the plant in Singapore will be the largest of six oil additive production sites owned by Evonik.
Evonik markets its oil additives under the brand name VISCOPLEX. Designed to improve productivity and fuel efficiency, they are a key component of formulated finished lubricants used in the automotive industry and other industrial applications.
We remind that, as MRC reported earlier, in June 2013, Evonik edching a new generation of PVC plasticizers under the ELATUR product brand. With this strategic portfolio expansion, Evonik is consistently developing its range of sustainable plasticizers. Besides, recently Evonik Industries has developed and launched on the market a novel combination of bio-based high-performance polyamides and bio-based high-performance fibers.
Evonik Industries is an industrial corporation in Germany and one of the world's leading specialty chemicals companies. Company's specialty chemicals activities focus on high-growth megatrends, especially, health, nutrition, resource efficiency, and globalization, and on entering attractive future-oriented markets. In 2012 Evonik generated sales of EUR13.6 billion and an operating result (adjusted EBITDA) of EUR2.6 billion.
MRC